Skip to main content

Table 1 Baseline characteristics of patients (N = 50)

From: Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial

Variable

  

Age, n (%)

  

   <65

40

(80)

   65 or more

10

(20)

Histotype, n (%)

  

   Ductal

41

(82)

   Lobular

6

(12)

   Other

3

(6)

ER status, n (%)

  

   Negative

19

(38)

   Positive

30

(60)

   Unknown

1

(2)

Performance status, n (%)

  

   0

41

(82)

   1

7

(14)

   2

2

(4)

HER2 status, n (%)

  

   Score 3+ by IHC

47

(94)

   Score 2+ and positive by FISH

3

(6)

Time from breast cancer diagnosis, n (%)

  

   <2 years

19

(38)

   2 years or more

31

(62)

Previous chemotherapy, n (%)

  

   No

9

(18)

   Yes

41

(82)

By type of drugs

  

CMF

4

(8)

with anthracycline

24

(48)

with anthracycline and taxane

13

(26)

By number of lines of chemotherapy

  

one line

26

(52)

two lines

15

(30)

Extension of disease, n (%)

  

   By number of involved organs

  

1

27

(54)

2

16

(32)

3

7

(14)

   By dominant metastatic site

  

soft tissues

13

(26)

viscera

37

(74)

Eligible for response assessment, n (%)

  

   No

10

(20)

   Yes

40

(80)

  1. IHC: immunohistochemistry, FISH: fluorescence in situ hybridization